- Open Access
Minimally invasive image-guided therapy for inoperable hepatocellular carcinoma: What is the evidence today?
© The Author(s) 2010
- Received: 24 February 2010
- Accepted: 28 May 2010
- Published: 1 June 2010
Hepatocellular carcinoma (HCC) is a primary malignant tumor of the liver that accounts for an important health problem worldwide. Only 10–15% of HCC patients are suitable candidates for hepatic resection and liver transplantation due to the advanced stage of the disease at time of diagnosis and shortage of donors. Therefore, several minimally invasive image-guided therapies for locoregional treatment have been developed. Tumor ablative techniques are either based on thermal tumor destruction, as in radiofrequency ablation, cryoablation, microwave ablation, laser ablation and high-intensity focused ultrasound, or chemical tumor destruction, as in percutaneous ethanol injection. Image-guided catheter-based techniques rely on intra-arterial delivery of embolic, chemoembolic or radioembolic agents. These minimally invasive image-guided therapies have revolutionized the management of inoperable HCC. This review provides a description of all minimally invasive image-guided therapies currently available, an up-to-date overview of the scientific evidence for their clinical use, and thoughts for future directions.
- Hepatocellular carcinoma
- Liver cancer
- Ablation techniques
- Intra-arterial infusion
Hepatocellular carcinoma (HCC) is a primary malignant tumor of the liver that accounts for an important health problem worldwide. Primary liver cancer is the sixth most common cancer worldwide with an incidence of 626,000 patients a year, and the third most common cause of cancer-related death . There is a striking geographic variation in the incidence of HCC throughout the world . The vast majority of HCC cases occur in developing countries, but incidence is on the rise in North America and Europe [3, 4].
HCC is a heterogeneous disease in terms of etiology and clinical behavior. It usually develops in the setting of chronic liver disease. Worldwide, the major risk factors for HCC are infection with the hepatitis B (HBV) and hepatitis C (HCV) viruses. In developing countries, HCC is mostly related to chronic HBV carrier state [5, 6]. Preventive vaccination against HBV infection has proven to effectively reduce the prevalence of HBV infection  and incidence of HCC . In developed countries, HCC arises in cirrhotic livers related to hepatitis C virus infection or excessive alcohol intake [9–12].
The development of effective therapeutic options for HCC is a major challenge and requires a multidisciplinary approach. Only 10–15% of HCC patients are suitable candidates for hepatic resection and liver transplantation due to the advanced stage of the disease at time of diagnosis and shortage of donors . Surgical resection is restricted to patients with solitary asymptomatic HCC and preserved liver function who have no clinically significant portal hypertension or increased bilirubin [17–19]. Unfortunately, no systemic chemotherapy has proven to be effective in HCC patients , except from the oral multi-kinase inhibitor Sorafenib in advanced stage patients with Child-Pugh liver function class A . In order to provide therapeutic options for patients with inoperable HCC, several minimally invasive image-guided therapies for locoregional treatment have been developed. HCC has a tendency to remain confined to the liver until the disease has advanced, making these treatments particularly attractive.
Minimally invasive image-guided therapies can be divided into the group of the tumor ablative techniques or the group of image-guided catheter-based techniques. Tumor ablative techniques are either based on thermal tumor destruction, as in radiofrequency ablation (RFA), cryoablation, microwave ablation, laser ablation and high-intensity focused ultrasound (HIFU), or chemical tumor destruction, as in percutaneous ethanol injection (PEI). These techniques are mostly used for early stage disease. Image-guided catheter-based techniques rely on intra-arterial delivery of embolic, chemoembolic, or radioembolic agents . These techniques enable treatment of large lesions or whole liver treatment, and are as such used for intermediate stage HCC (Figure 1).
Minimally invasive image-guided ablation techniques and intra-arterial interventions may prolong survival, spare more functioning liver tissue in comparison to surgical resection (which can be very important in cirrhotic patients), allow retreatment if necessary, and may be an effective bridge to transplantation [23–27].
During the last 2 decades, minimally invasive image-guided therapies have revolutionized the management of inoperable HCC. This review provides an overview of the different interventional techniques that are currently available in clinical practice, the scientific evidence for their clinical use, and thoughts for future directions.
Accurate imaging is of great importance during minimally invasive locoregional therapies to efficiently guide and monitor the treatment. It enables proper placement of instruments, like the probe in case of ablation or the catheter in case of intra-arterial therapy, and accurate monitoring of the progression of the necrotic zone during ablation. Fluoroscopy, ultrasound (US), computed tomography (CT), and magnetic resonance imaging (MRI) can all be employed. In current clinical practice, placement of the catheter in intra-arterial procedures is usually performed under fluoroscopic guidance, while ablation may be guided by ultrasound, CT or MRI.
Ultrasound guidance allows probe insertion from every angle, offers real time visualization and correction for motion artifacts when targeting the tumor, and is low cost. However, the gas created during ablation (or ice in the case of cryoablation) hampers penetration of the ultrasound beams in tissue, causing acoustic shadowing and obscuring image details like the delineation between tumor borders and ablation zone.
CT is also frequently used to guide minimally invasive ablation therapy, and is a reliable modality to confirm treatment results. In comparison to US, it provides increased lesion discrimination, a more reliable depiction of ablated/non-ablated interfaces, and a better correlation to pathologic size . However, due to its hypervascularity, small HCCs can only be clearly visualized in the arterial phase for a short period of time. Another disadvantage of CT is the exposure of the patient and physician to ionizing radiation. Combining US imaging for probe placement and CT for ablation monitoring reduces this exposure. At the moment, hybrid systems are being developed, enabling combination of imaging techniques, like ultrasound and CT imaging, thereby improving the registration accuracy during treatment .
The interest in MRI-guided ablation is growing, as it produces a high-quality image allowing high-sensitivity tumor detection and accurate identification of the target region with multiplanar imaging. MRI also enables real-time monitoring of the temperature evolution during treatment[30–35]. However, MRI is an expensive technique, and MRI-guided ablation is still limited in clinical practice.
Percutaneous ethanol injection
Prior to the clinical introduction of thermal tumor ablation techniques, percutaneous ethanol injection (PEI) was widely used for treatment of HCC. PEI was introduced into clinical practice in the 1980s, being the first percutaneous treatment for HCC [36, 37]. With this technique, 95% ethanol is injected directly into the tumor, using ultrasound or CT guidance. Ethanol induces local tumor necrosis as a result of cellular dehydration, protein denaturation, and chemical occlusion of tumor vessels.
Best results are seen with small, uninodular tumors of 3 cm or less, with response rates approaching 100% [39, 40]. Repeated procedures are often needed to obtain complete tumor ablation, especially for larger lesions. Three-year survival rates of 79%, 63%, and 12% have been reported for patients with single HCC of 5 cm or smaller with Child-Pugh cirrhosis class A, B or C, respectively . Complications of PEI consist of local pain, fever, and abscess formation .
While PEI proved to be a valuable treatment for preferably small HCC lesions, several randomized controlled trials indicate that its effectiveness in small HCCs is outrun by RFA [39, 43–46]. These studies indicate that RFA is superior to PEI with respect to overall survival, cancer-free survival rates, local recurrence, and tumor response. Nowadays, PEI is used when thermal ablation such as RFA cannot be performed safely, for example, in cases in which the tumor is located in close proximity to bowel loops, bile ducts, or other sites in which thermal ablative techniques are risky.
It is difficult to draw definite conclusions about the efficacy of RFA, as most published data consist of non-randomized uncontrolled cohort studies. The differences in outcome measures, techniques, approaches and RFA electrode designs in these studies add complexity to interpretation of these data.
Predictors of complete ablation (or complete response) are small size (≤3 cm) tumors and well-differentiated and non-infiltrative HCCs . Several studies have reported complete ablation rates of 80–100% in HCCs ≤ 3 cm, 50–80% in HCCs 3–5 cm, and 25% in HCCs >5 cm[39, 43–45, 51, 52].
Long-term survival data from follow-up studies of HCC patients treated with RFA
Type of RFA
Tumor size (cm)
5-year overall survival (%)
Buscarini et al. (2001)
Lencioni et al. (2005)
Tateishi et al. (2005)
Raut et al. (2005)
Machi et al. (2005)
Cabassa et al. (2006)
Choi et al. (2006)
Yan et al. (2007)
Ueno et al. (2009)
110 perc, 45
RFA is most effective against small tumors; technological limitations hinder ablation of tumors with a larger diameter. Developments in technology, like more powerful generators or bipolar multiprobe arrays, and technical maneuvers, like the application of selective vascular occlusion to reduce the ‘heat sink’ cooling effect of flowing blood, have allowed treatment of larger tumors [62–67]. Some authors have reported that RFA may be a safe and effective bridge to liver transplantation over a prolonged waiting period .
Percutaneous image-guided RFA of HCC is associated with a very low mortality and acceptable morbidity. Three separate multicenter studies have reported mortality rates ranging from 0.1% to 0.5%, major complication rates ranging from 2.2% to 3.1% and minor complication rate ranging from 5% to 8.9% .
One important issue with RFA is the problem of needle-track seeding, which was reported in one study at a rate of 12.5% , although more recent studies show less alarming rates, ranging from 0.9% to 4% [70–72]. Needle biopsy before treatment, poor differentiation degree of the tumor, subcapsular lesions, patients treated in multiple sessions, and lesions requiring more than one electrode placement were identified as risk factors. Viable tumor cells adherent to the needle applicators were found in 12.5% of patients after ablation without track ablation . To prevent tumor seeding as well as to create hemostasis, ablation along the access track is recommended. Despite the risk of needle-track seeding, RFA is considered a curative treatment for small HCC lesions, and there is ongoing debate whether RFA could potentially be considered a first option for operable patients with very early stage HCC (BCLC stage 0) [74, 75]. In a prospective randomized controlled trial (RCT) comparing percutaneous RFA to surgical resection in 180 patients with solitary HCCs <5 cm in diameter, no differences in overall survival rates and cumulative recurrence-free survival rates were observed .
In the BCLC staging classification, patients with early stage asymptomatic HCC with a single nodule <5 cm or smaller or up to three nodules <3 cm and Child-Pugh class A or B cirrhosis are referred to RFA.
Cryoablation is a technique in which a liquid nitrogen-cooled cryoprobe is placed into the tumor and an ice ball is created in the target tissue. The freezing of tissue with temperatures between −20°C and −60°C followed by rapid thawing results in cell membrane disruption and induces cell death . Cryoablation can be carried out in an open procedure, by laparoscopy, and percutaneously. Ultrasound guidance assures proper placement of the cryoprobe and enables monitoring of the ablation area. An advantage of this technique is that it can be applied for larger tumors up to 8 cm, whereas in most tumor ablative techniques only small tumors can be successfully treated . In most published studies, cryotherapy was conducted in unresectable HCC either alone or in combination with other treatment modalities, e.g., as a complement to resection to achieve total tumor eradication in otherwise unresectable patients, and long-term survival rates of 20–40% have been described [79, 80]. However, this technique has fallen out of favor for the treatment of HCC, primarily because of the complication rate described as high as 40.7%  and the risk of ‘cryoshock,’ a life-threatening condition resulting in multiorgan failure, severe coagulopathy and disseminated intravascular coagulation following cryoablation, which has been described at a rate of 1% . There are currently no randomized trials that support the use of hepatic cryoablation for HCC treatment.
Microwave ablation (MWA) induces thermal tumor destruction by induction of an alternating electric field emitted by a bipolar antenna, which is placed centrally in the tumor. Several groups have successfully proven the safety and efficacy of MWA treatment, mostly in small HCCs [83, 84]. Dong et al. reported satisfactory long-term results in larger HCCs. They treated 234 patients with a mean tumor size of 4.1 ± 1.9 cm (range 1.2–8.0 cm) and reported a 5-year cumulative survival rate of 57%. Liang et al. treated 288 HCC patients with a mean tumor size of 3.75 cm ±1.58 (range 1.2–8.0 cm) and reported a 5-year cumulative survival rate of 51%. Child-Pugh classification, tumor size, and number of tumors were identified as significant independent prognostic factors. They concluded that there is a significantly higher probability of long-term survival after MWA treatment for patients with a single tumor of 4.0 cm or less and Child-Pugh class A cirrhosis . Reported complications of MWA are similar to those reported for RFA and are typically mild, including pain, fever, liver enzyme elevation, ascites, pleural effusion, and diaphragm injury.
MWA has been compared to other ablative techniques in several studies. Seki et al. retrospectively compared MWA to PEI for small HCCs (≤2 cm). They concluded that MWA may be superior to PEI for the local control of moderately or poorly differentiated small HCCs . Ohmoto et al. compared MWA to RFA for small HCCs. They suggested that RFA is more useful for the treatment of small HCCs (≤2 cm) compared to MWA, since RFA resulted in a larger area of necrosis, needed fewer treatment sessions, and showed a lower recurrence rate and higher survival rate (4-year survival 70% versus 39%) [88–90]. However, Lu et al. performed a retrospective comparative study and concluded that MWA and RFA were both effective methods in treating HCC [mean tumor diameter respectively 2.5 cm ±1.2 (range 0.9–7.2 cm) and 2.6 cm ±1.2 (range 1.0–6.1 cm)]. Local tumor control, complications related to treatment, and long-term survival (4-year survival 37% for MWA versus 24% for RFA, P = 0.12) were equivalent for the two modalities . It needs to be noted that the level of evidence of these studies is limited since they describe only a retrospective comparison of the two procedures. The only randomized study comparing MWA and RFA showed that both techniques had equivalent therapeutic effects, complication rates, and rates of residual foci of untreated disease. However, RFA offers the advantage of tumor ablation being achieved in fewer sessions (2.4 versus 1.1) .
In conclusion, experience with MWA of HCC is limited and still in its early stage. Preliminary work has shown that microwave ablation might be a viable alternative to other ablation techniques. Further prospective randomized studies evaluating local control, symptom palliation, and survival in a larger number of patients are necessary.
In laser ablation, also frequently called laser-induced thermotherapy (LITT), a percutaneously placed optical fiber delivers laser beams into the target tumor . The energy from the photons absorbed in the tissue converts into heat, inducing coagulative necrosis. The most commonly used device for laser ablation is the Nd-YAG laser (neodymium-yttrium-aluminum-garnet laser). Most frequently, near-infrared wavelength optical radiation is used, since this accomplishes the best tissue penetration . The positioning of the fibers is guided by ultrasound, CT, or MRI. A single-probe insertion can only create a small volume of ablation, so often multiple optical fibers have to be placed for treatment of larger lesions (>5 cm), which may be technically cumbersome and result in long treatment times. Selection criteria for LITT are broadly similar to those of other ablative techniques. Ideal lesions are less than 3 cm in diameter and located deep within the liver parenchyma .
LITT has been proven safe and feasible for the treatment of HCCs in multiple cohort studies[96–102]. Pacella et al. performed three studies in which they reported 3- and 5-year survival rates ranging from 52% to 68% and 15% to 34%, respectively [96, 98, 99]. They included patients with a single nodule ≤4 cm or three nodules ≤3 cm each. Tumor size, tumor location, and the achievement of complete response were important factors that affected survival after treatment. They stated that the ideal candidates for LITT are those with normal bilirubin levels and a small tumor size (≤2 cm) [97–99]. According to Arienti et al., who performed a multicenter study with 353 patients to investigate complications, LITT is a safe treatment with a major complication rate of 1.5% (0.8% deaths) and a minor complication rate of 6.2%. They also stated that complete response was achieved in 60%, regardless of tumor size, and in 81% in lesions ≤3 cm HCCs . Tumor seeding after treatment has not been reported. LITT has also been proven safe and effective for the treatment of cirrhotic patients awaiting liver transplantation. There is one randomized trial in which LITT is compared to RFA for treatment of early stage HCC (nodule ≤4 cm or three nodules ≤3 cm each). They found LITT and RFA to be equally effective; however, in the case of RFA fewer treatment sessions were needed to achieve complete response . More randomized controlled trials should be carried out to compare LITT to other ablative techniques and to investigate the role of LITT in combination therapy.
High-intensity focused ultrasound
In high-intensity focused ultrasound (HIFU), an extracorporeal transducer produces high-energy ultrasound (US) beams that propagate harmlessly through the intact skin and are brought into a tight focus (1–3 mm) within the tumor. The rapid deposition of acoustic energy leads to an instantaneous temperature increase of >55°C within the tissue, inducing coagulation necrosis . HIFU offers the first completely non-invasive approach to HCC and is therefore a promising technology. In current practice, both conventional ultrasound and MRI are used to guide and monitor HIFU treatment. MRI offers one important advantage over US guidance, as it enables accurate monitoring of the temperature during treatment .
There are only a few clinical reports on the application of HIFU for HCC treatment. The majority of work is published by two groups [106, 107], who both use real-time US-guidance during treatment. Wu et al. report that HIFU treatment is effective, safe, and feasible in patients with large HCCs . They treated 55 patients with a mean tumor diameter of 8.14 cm ± 3.37 (range 4-14 cm) . Overall survival rates at 6, 12, and 18 months were respectively 86.1%, 61.5%, and 35.3%. The survival rates were higher in patients with less advanced disease according to the TNM classification. It has to be noted however that pre-procedural TACE was carried out in half of the patients and that rib resection was performed in 14 patients, taking away the non-invasive character of the procedure. In another study by Zhu et al., ribs were removed in all patients to create a better acoustic pathway. Sixteen HCC patients were treated with US-guided HIFU with a mean tumor diameter of 7.0 cm ± 2.1 (range 5–10 cm). The 3- and 5-year survival rates were 69.3% and 55.6%, respectively . As the results of these studies indicate, there are some difficulties that need to be overcome before HIFU can be used in everyday clinical practice for non-invasive treatment of HCC. The presence of the rib cage presents a problem, since the high attenuation of the ribs results in a loss of power at the focus, and reflection of the beams may induce injury to the overlying soft tissues and the skin, which may also happen when US encounters an air-filled bowel loop. However, technical solutions are underway. Civale et al. reported that this problem can be avoided by the use of a segmented transducer . Liu et al. proposed to reduce the rib-overheating problem by using an independent array-element activation scheme, which switches off the transducer elements obstructed by the ribs based on feedback anatomical medical imaging . Another challenge in HIFU for HCC treatment is the difficulty in targeting and monitoring since the liver is subject to respiratory movements. The main limitation to clinical use of HIFU is the fact that ablation of large volumes of the liver is still very time consuming. Next-generation phased-array transducers and advanced MRI methods are being developed to overcome these difficulties.
Transcatheter arterial chemoembolization
Transcatheter arterial chemoembolization (TACE) is a technique that exploits the dual blood supply to the liver. HCC derives its blood supply almost entirely from the hepatic artery, while normal liver parenchyma derives >75% of its blood supply from the portal vein . This anatomical fact provides the basis for the development of arterial therapies for the treatment of HCC, with the potential to selectively induce tumor necrosis while surrounding liver parenchyma is spared.
In TACE, a catheter is advanced into the branches of the hepatic artery directly supplying the tumor, and a highly concentrated dose of chemotherapy is delivered intra-arterially in close proximity to the tumor so that systemic toxicity is minimized. The most commonly used single chemotherapeutic agent is doxorubicin. The combination of cisplatin, doxorubicin, and mitomycin C is the most common combination drug regimen. However, to date there is no evidence of the superiority of any chemotherapeutic agent alone or of monotherapy versus combination therapy in TACE [111, 112]. The chemotherapeutic agent is usually mixed with an embolic agent such as lipiodol, an oily contrast medium used as a carrier for the chemotherapeutic agent and known to be selectively retained inside the tumor, thereby prolonging contact time between the drugs and the tumor cells [113, 114]. The administration of the lipiodolized chemotherapeutic agent is followed by injection of an occluding agent. The purpose of the embolization is to reduce arterial inflow, resulting in ischemic tumor necrosis, and to diminish washout of the chemotherapeutic agent thereby prolonging contact time between cancer cells and the chemotherapeutic agent . Multiple TACE protocols are used throughout the world, and the optimal method is yet to be established.
Survival data from randomized controlled trials investigating TACE in HCC patients
1-year overall survival (%)
2-year overall survival (%)
3-year overall survival (%)
Lin et al. (1988)
21 TAE + 5-FU iv
21 5-FU iv
Pelletier et al. (1990)
Groupe d’Etude (1995)
Pelletier et al. (1998)
Lo et al. (2002)
Llovet et al. (2002)
TACE is typically well tolerated. The major side effect of TACE is the so-called postembolization syndrome, consisting of transient abdominal pain, ileus, and fever, probably due to damage of hepatocytes. It effects 40%–85% of patients and is usually self-limited within 48 h . A serious complication of TACE is acute liver failure. The potential risk for this condition, which increases with larger tumors, underlying liver dysfunction and presence of portal vein thrombosis, limits the use of TACE. Other more serious treatment-related complications (hepatic abcess, ischemic cholecystitis, biliary strictures) appear in less than 10% of treatment sessions . The side effects of the chemotherapeutic agents in TACE are mild and have a low rate, compared with those caused by systemic chemotherapy, and can be managed conservatively. They include nausea, vomiting, bone marrow depression, alopecia, and renal dysfunction [125, 126].
To conclude, TACE is currently the treatment of choice for multinodular, intermediate stage HCC (Fig. 1, BCLC stage B) and to be preferred over best supportive care.
Transcatheter arterial (bland) embolization
Transcatheter arterial embolization (TAE or bland embolization) consists of embolizing the artery feeding the tumor, without the use of a chemotherapeutic agent. The exact benefit of administering chemotherapy during the embolization procedure is uncertain, since HCC is known to be chemoresistant. However, hypoxia is known to be a potent stimulator of angiogenesis, and since angiogenesis is vital for tumor growth, hypoxia induced by embolization might inadvertently promote tumor growth . Adding a chemotherapeutic agent may counteract this effect. No comparative clinical study to date has proven evidence of survival favoring TACE over TAE . However, in recent years, TACE has replaced TAE as the most widely used and studied treatment modality for intermediate stage HCC .
Although conventional TACE has been shown to improve survival, the magnitude of this benefit is relatively small, so the search for more effective drug delivery systems continues. A novel development in the treatment for HCC is the drug-eluting bead (DEB), a polyvinyl alcohol-based microsphere loaded with a chemotherapeutic agent, usually doxorubicin. These microspheres are available in diameters ranging from 40 to 1,200 µm. The DEB is delivered intra-arterially in a manner similar to that of conventional TACE and acts as both an occluding agent as well as a drug-loaded carrier (Fig. 4). Local ischemia and toxic death of the tumor are achieved with one device, enabling standardization. DEBs have favorable kinetics achieving higher tumor concentrations with lower plasma levels of the chemotherapic agent compared to conventional TACE [129, 130]. In DEBs, drug elution is dependent on ion exchange with the surrounding environment. This results in a controlled and sustained gradual release of the drug—unlike the more rapid separation of the drug from lipiodol—prolonging the exposure of tumor cells .
Recently performed clinical trials reported the efficacy of DEBs in the treatment of intermediate stage HCC [130, 132–135], with good objective response (complete plus partial response) rates ranging 60%–85.5% (according to the EASL response criteria). The complication rates in these clinical trials ranged between 3 and 11.4%, and post-embolisation syndrome was observed in various severities in 18% , 37%  and 100% [133, 134]. Most important, there are no reports of systemic toxicity, despite the high doses of doxorubicin loaded on the DEBs. Information on survival rates is still limited up to today, but midterm survival rates seem promising with 2-year survival up to 91% . RCTs comparing conventional TACE to TACE-DEB are currently underway.
The use of traditional external beam radiation for the treatment of HCC has been limited because of the inability to deliver an effective dose without damaging the adjacent hepatic parenchyma, resulting in radiation-induced liver disease (RILD), previously called radiation-induced hepatitis [136–138]. Radioembolization (RE) implements intra-arterial administration of microspheres coated with yttrium-90 (90Y), a ß-emitting isotope, delivering selective internal radiation to the tumor. Exposure to surrounding healthy tissue is limited, avoiding injury to the normal liver parenchyma . This technique was first described in 1965, and in recent years clinical investigation has intensified. The procedure is compromised by two components: embolization, with a micro-or macro-embolic effect, depending on the size of the microsphere, and brachytherapy [139, 141] (Figs. 5, 6). Two types of Y90 microspheres are in clinical use at present: glass microspheres (TheraSphere®, MDS Nordion Inc., Kanata, Canada) and resin-based microspheres (SIR-Spheres®, SIRTeX Medical Ltd., Sydney, Australia).
Tumor response and median survival after 90Y-RE in HCC patients
Tumor response on CTa
Median survival (months)
Lau et al. (1998)
Dancey et al. (2000) 
20 (19 evaluated for response)
Carr et al. (2004)
Okuda I: 21.3, Okuda II: 9.9
Geschwind et al. (2004)
Okuda I: 20.6, Okuda II: 12.6
Low risk: 15.3, high risk: 3.5
Okuda I: 24.4, Okuda II: 12.5
24 (21 evaluated for response)
88c (PR + SD)
Okuda I: 21.7, Okuda II: 14.2
No PVT: 15.4, branch PVT: 10.0, main PVT: 4.4
90Y-RE has a low toxicity profile and can be performed on an outpatient basis, with low incidence of a mild post-embolization syndrome [147, 153]. Due to the minimally embolic effect of 90Y-RE glass microspheres, this offers a safe treatment with favorable tumor response rates for patients with portal vein thrombosis .
Absolute contraindications for 90Y-RE treatment are significant hepatopulmonary shunting or flow to the gastrointestinal tract that cannot be corrected by catheter manipulation, demonstrated by a pre-treatment 99mTc macro-aggregated albumin (MAA) examination . Inadvertent deposition of 90Y microspheres to the lungs or gastrointestinal tract can result in serious complications like radiation pneumonitis, cholecystitis, gastric ulceration, or pancreatitis pneumonitis[154–157]. The antitumor effect of 90Y-RE allows for the downstaging of unresectable HCC to potentially curative treatments, like surgical resection, percutaneous ablation, and bridging to liver transplantation[158–160]. Although several studies have provided useful data, there is a need for further investigation of this therapy and randomized trials comparing the efficacy of 90Y-RE to other minimally invasive locoregional therapies.
HCC is a heterogeneous cancer with an increasing incidence and poor prognosis. Curative therapy is only applicable to patients diagnosed at early stages of disease, emphasizing the importance of screening programs for at-risk patients. Minimally invasive image-guided ablation techniques and intra-arterial interventions offer promising potential for patients with HCC not suitable for surgical resection or transplantation.
According to the BCLC criteria, RFA is currently considered the treatment of choice for patients with unresectable small HCCs (early stage, stage A). TACE is the treatment of choice for the management of multinodular HCC (intermediate stage, stage B), preferably in asymptomatic patients with well-preserved liver function (Child-Pugh class A). Sorafenib, an oral multitargeted tyrosine kinase inhibitor, has become the standard of care in advanced stage patients (stage C) with vascular involvement, extrahepatic spread or physical impairment (Child-Pugh A, ECOG performance status test score 1–2). Targeted molecular therapies like Sorafenib represent the beginning of a new era in the treatment of HCC. Finally, patients at a terminal stage (stage D) who have very impaired physical status (performance status test score >2) or tumor burden (stage D) should receive symptomatic treatment.
For most tumor ablative techniques, increasing tumor diameter decreases the likelihood of complete ablation. The combination of local ablation and intra-arterial therapies may help overcome shortcomings of monotherapy treatment for larger tumors, and diverse studies have shown promising potential.
A randomized controlled study showed that concomitant RFA-PEI facilitated better local tumor control and long-term survival compared to RFA alone, with 5-year overall survival rates of 49.3% versus 35.9% . A meta-analysis of four randomized controlled trials [162–165] that investigated the combination of TACE or TAE plus percutaneous ablation (PEI or RFA) for the treatment of HCC showed a significant decrease in mortality favoring combination treatment compared to monotherapy (TAE, TACE, or percutaneous ablation only). In addition, there is high interest in combining local therapies with targeted molecular therapies like Sorafenib.
With ongoing research, existing image-guided local therapies will be further optimized, and promising new therapies will emerge. Combination of treatments, new technologies in imaging, and targeted drug delivery will ultimately improve the quality of life and survival of patients with HCC.
- Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55:74–108PubMedGoogle Scholar
- [No authors listed] (1987) Hepatocellular cancer: differences between high and low incidence regions. Lancet 2:1183–1184Google Scholar
- El-Serag HB, Davila JA, Petersen NJ, McGlynn KA (2003) The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med 139:817–823PubMedGoogle Scholar
- Taylor-Robinson SD, Foster GR, Arora S, Hargreaves S, Thomas HC (1997) Increase in primary liver cancer in the UK, 1979–94. Lancet 350:1142–1143PubMedGoogle Scholar
- Beasley RP, Hwang LY, Lin CC, Chien CS (1981) Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22,707 men in Taiwan. Lancet 2:1129–1133PubMedGoogle Scholar
- Beasley RP (1988) Hepatitis B virus. The major etiology of hepatocellular carcinoma Cancer 61:1942–1956PubMedGoogle Scholar
- Chen HL, Chang MH, Ni YH, Hsu HY, Lee PI, Lee CY et al (1996) Seroepidemiology of hepatitis B virus infection in children: Ten years of mass vaccination in Taiwan. JAMA 276:906–908PubMedGoogle Scholar
- Chang MH, Chen CJ, Lai MS, Hsu HM, Wu TC, Kong MS et al (1997) Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl J Med 336:1855–1859PubMedGoogle Scholar
- Adami HO, Hsing AW, McLaughlin JK, Trichopoulos D, Hacker D, Ekbom A et al (1992) Alcoholism and liver cirrhosis in the etiology of primary liver cancer. Int J Cancer 51:898–902PubMedGoogle Scholar
- Bruix J, Barrera JM, Calvet X, Ercilla G, Costa J, Sanchez-Tapias JM et al (1989) Prevalence of antibodies to hepatitis C virus in Spanish patients with hepatocellular carcinoma and hepatic cirrhosis. Lancet 2:1004–1006PubMedGoogle Scholar
- Colombo M, Kuo G, Choo QL, Donato MF, Del NE, Tommasini MA et al (1989) Prevalence of antibodies to hepatitis C virus in Italian patients with hepatocellular carcinoma. Lancet 2:1006–1008PubMedGoogle Scholar
- Tsukuma H, Hiyama T, Tanaka S, Nakao M, Yabuuchi T, Kitamura T et al (1993) Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med 328:1797–1801PubMedGoogle Scholar
- Pons F, Varela M, Llovet JM (2005) Staging systems in hepatocellular carcinoma. HPB (Oxford) 7:35–41Google Scholar
- Llovet JM, Fuster J, Bruix J (2004) The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma. Liver Transpl 10:S115–S120PubMedGoogle Scholar
- Bruix J, Llovet JM (2009) Major achievements in hepatocellular carcinoma. Lancet 373:614–616PubMedGoogle Scholar
- Geschwind JF (2002) Chemoembolization for hepatocellular carcinoma: where does the truth lie? J Vasc Interv Radiol 13:991–994PubMedGoogle Scholar
- Bruix J, Llovet JM (2002) Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology 35:519–524PubMedGoogle Scholar
- Bruix J, Castells A, Bosch J, Feu F, Fuster J, Garcia-Pagan JC et al (1996) Surgical resection of hepatocellular carcinoma in cirrhotic patients: prognostic value of preoperative portal pressure. Gastroenterology 111:1018–1022PubMedGoogle Scholar
- Llovet JM, Fuster J, Bruix J (1999) Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology 30:1434–1440PubMedGoogle Scholar
- Thomas MB, O’Beirne JP, Furuse J, Chan AT, bou-Alfa G, Johnson P (2008) Systemic therapy for hepatocellular carcinoma: cytotoxic chemotherapy, targeted therapy and immunotherapy. Ann Surg Oncol 15:1008–1014PubMedGoogle Scholar
- Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF et al (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378–390PubMedGoogle Scholar
- Trinchet JC, Ganne-Carrie N, Beaugrand M (2003) Review article: intra-arterial treatments in patients with hepatocellular carcinoma. Aliment Pharmacol Ther 17(Suppl 2):111–118PubMedGoogle Scholar
- Lu DS, Yu NC, Raman SS, Lassman C, Tong MJ, Britten C et al (2005) Percutaneous radiofrequency ablation of hepatocellular carcinoma as a bridge to liver transplantation. Hepatology 41:1130–1137PubMedGoogle Scholar
- Mazzaferro V, Battiston C, Perrone S, Pulvirenti A, Regalia E, Romito R et al (2004) Radiofrequency ablation of small hepatocellular carcinoma in cirrhotic patients awaiting liver transplantation: a prospective study. Ann Surg 240:900–909PubMedPubMed CentralGoogle Scholar
- Graziadei IW, Sandmueller H, Waldenberger P, Koenigsrainer A, Nachbaur K, Jaschke W et al (2003) Chemoembolization followed by liver transplantation for hepatocellular carcinoma impedes tumor progression while on the waiting list and leads to excellent outcome. Liver Transpl 9:557–563PubMedGoogle Scholar
- Yao FY, Kerlan RK, Hirose R, Davern TJ, Bass NM, Feng S et al (2008) Excellent outcome following down-staging of hepatocellular carcinoma prior to liver transplantation: an intention-to-treat analysis. Hepatology 48:819–827PubMedPubMed CentralGoogle Scholar
- Chapman WC, Majella Doyle MB, Stuart JE, Vachharajani N, Crippin JS, Anderson CD et al (2008) Outcomes of neoadjuvant transarterial chemoembolization to downstage hepatocellular carcinoma before liver transplantation. Ann Surg 248:617–625PubMedGoogle Scholar
- Cha CH, Lee FT Jr, Gurney JM, Markhardt BK, Warner TF, Kelcz F et al (2000) CT versus sonography for monitoring radiofrequency ablation in a porcine liver. AJR Am J Roentgenol 175:705–711PubMedGoogle Scholar
- Wood BJ, Locklin JK, Viswanathan A, Kruecker J, Haemmerich D, Cebral J et al (2007) Technologies for guidance of radiofrequency ablation in the multimodality interventional suite of the future. J Vasc Interv Radiol 18:9–24PubMedPubMed CentralGoogle Scholar
- Hokland SL, Pedersen M, Salomir R, Quesson B, Stodkilde-Jorgensen H, Moonen CT (2006) MRI-guided focused ultrasound: methodology and applications. IEEE Trans Med Imaging 25:723–731PubMedGoogle Scholar
- Cline HE, Hynynen K, Watkins RD, Adams WJ, Schenck JF, Ettinger RH et al (1995) Focused US system for MR imaging-guided tumor ablation. Radiology 194:731–737PubMedGoogle Scholar
- Hynynen K, Freund WR, Cline HE, Chung AH, Watkins RD, Vetro JP et al (1996) A clinical, noninvasive, MR imaging-monitored ultrasound surgery method. Radiographics 16:185–195PubMedGoogle Scholar
- Kopelman D, Inbar Y, Hanannel A, Dank G, Freundlich D, Perel A et al (2006) Magnetic resonance-guided focused ultrasound surgery (MRgFUS). Four ablation treatments of a single canine hepatocellular adenoma HPB (Oxford) 8:292–298Google Scholar
- Kopelman D, Inbar Y, Hanannel A, Freundlich D, Castel D, Perel A et al (2006) Magnetic resonance-guided focused ultrasound surgery (MRgFUS): ablation of liver tissue in a porcine model. Eur J Radiol 59:157–162PubMedGoogle Scholar
- Gedroyc WM (2005) Magnetic resonance guidance of thermal ablation. Top Magn Reson Imaging 16:339–353PubMedGoogle Scholar
- Livraghi T, Festi D, Monti F, Salmi A, Vettori C (1986) US-guided percutaneous alcohol injection of small hepatic and abdominal tumors. Radiology 161:309–312PubMedGoogle Scholar
- Shiina S, Yasuda H, Muto H, Tagawa K, Unuma T, Ibukuro K et al (1987) Percutaneous ethanol injection in the treatment of liver neoplasms. AJR Am J Roentgenol 149:949–952PubMedGoogle Scholar
- Lencioni R, Cioni D, Crocetti L, Bartolozzi C (2004) Percutaneous ablation of hepatocellular carcinoma: state-of-the-art. Liver Transpl 10:S91–S97PubMedGoogle Scholar
- Shiina S, Teratani T, Obi S, Sato S, Tateishi R, Fujishima T et al (2005) A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. Gastroenterology 129:122–130PubMedGoogle Scholar
- Lencioni R, Bartolozzi C, Caramella D, Paolicchi A, Carrai M, Maltinti G et al (1995) Treatment of small hepatocellular carcinoma with percutaneous ethanol injection. Analysis of prognostic factors in 105 Western patients. Cancer 76:1737–1746PubMedGoogle Scholar
- Livraghi T, Giorgio A, Marin G, Salmi A, De Sio I, Bolondi L et al (1995) Hepatocellular carcinoma and cirrhosis in 746 patients: long-term results of percutaneous ethanol injection. Radiology 197:101–108PubMedGoogle Scholar
- Di SM, Buscarini L, Livraghi T, Giorgio A, Salmi A, De Sio I et al (1997) Percutaneous ethanol injection in the treatment of hepatocellular carcinoma. A multicenter survey of evaluation practices and complication rates Scand J Gastroenterol 32:1168–1173Google Scholar
- Lencioni RA, Allgaier HP, Cioni D, Olschewski M, Deibert P, Crocetti L et al (2003) Small hepatocellular carcinoma in cirrhosis: randomized comparison of radio-frequency thermal ablation versus percutaneous ethanol injection. Radiology 228:235–240PubMedGoogle Scholar
- Lin SM, Lin CJ, Lin CC, Hsu CW, Chen YC (2004) Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma ≤4 cm. Gastroenterology 127:1714–1723PubMedGoogle Scholar
- Lin SM, Lin CJ, Lin CC, Hsu CW, Chen YC (2005) Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3 cm or less. Gut 54:1151–1156PubMedPubMed CentralGoogle Scholar
- Brunello F, Veltri A, Carucci P, Pagano E, Ciccone G, Moretto P et al (2008) Radiofrequency ablation versus ethanol injection for early hepatocellular carcinoma: A randomized controlled trial. Scand J Gastroenterol 43:727–735PubMedGoogle Scholar
- Orlando A, Leandro G, Olivo M, Andriulli A, Cottone M (2009) Radiofrequency thermal ablation vs. percutaneous ethanol injection for small hepatocellular carcinoma in cirrhosis: meta-analysis of randomized controlled trials. Am J Gastroenterol 104:514–524PubMedGoogle Scholar
- Curley SA, Izzo F, Delrio P, Ellis LM, Granchi J, Vallone P et al (1999) Radiofrequency ablation of unresectable primary and metastatic hepatic malignancies: results in 123 patients. Ann Surg 230:1–8PubMedPubMed CentralGoogle Scholar
- Curley SA, Izzo F, Ellis LM, Nicolas VJ, Vallone P (2000) Radiofrequency ablation of hepatocellular cancer in 110 patients with cirrhosis. Ann Surg 232:381–391PubMedPubMed CentralGoogle Scholar
- Goldberg SN, Gazelle GS, Solbiati L, Livraghi T, Tanabe KK, Hahn PF et al (1998) Ablation of liver tumors using percutaneous RF therapy. AJR Am J Roentgenol 170:1023–1028PubMedGoogle Scholar
- Livraghi T, Goldberg SN, Lazzaroni S, Meloni F, Ierace T, Solbiati L et al (2000) Hepatocellular carcinoma: radio-frequency ablation of medium and large lesions. Radiology 214:761–768PubMedGoogle Scholar
- Livraghi T, Goldberg SN, Lazzaroni S, Meloni F, Solbiati L, Gazelle GS (1999) Small hepatocellular carcinoma: treatment with radio-frequency ablation versus ethanol injection. Radiology 210:655–661PubMedGoogle Scholar
- Buscarini L, Buscarini E, Di SM, Vallisa D, Quaretti P, Rocca A (2001) Percutaneous radiofrequency ablation of small hepatocellular carcinoma: long-term results. Eur Radiol 11:914–921PubMedGoogle Scholar
- Lencioni R, Cioni D, Crocetti L, Franchini C, Pina CD, Lera J et al (2005) Early-stage hepatocellular carcinoma in patients with cirrhosis: long-term results of percutaneous image-guided radiofrequency ablation. Radiology 234:961–967PubMedGoogle Scholar
- Tateishi R, Shiina S, Teratani T, Obi S, Sato S, Koike Y et al (2005) Percutaneous radiofrequency ablation for hepatocellular carcinoma. An analysis of 1,000 cases. Cancer 103:1201–1209PubMedGoogle Scholar
- Raut CP, Izzo F, Marra P, Ellis LM, Vauthey JN, Cremona F et al (2005) Significant long-term survival after radiofrequency ablation of unresectable hepatocellular carcinoma in patients with cirrhosis. Ann Surg Oncol 12:616–628PubMedGoogle Scholar
- Machi J, Bueno RS, Wong LL (2005) Long-term follow-up outcome of patients undergoing radiofrequency ablation for unresectable hepatocellular carcinoma. World J Surg 29:1364–1373PubMedGoogle Scholar
- Cabassa P, Donato F, Simeone F, Grazioli L, Romanini L (2006) Radiofrequency ablation of hepatocellular carcinoma: long-term experience with expandable needle electrodes. AJR Am J Roentgenol 186:S316–S321PubMedGoogle Scholar
- Choi D, Lim HK, Rhim H, Kim YS, Lee WJ, Paik SW et al (2007) Percutaneous radiofrequency ablation for early-stage hepatocellular carcinoma as a first-line treatment: long-term results and prognostic factors in a large single-institution series. Eur Radiol 17:684–692PubMedGoogle Scholar
- Yan K, Chen MH, Yang W, Wang YB, Gao W, Hao CY et al (2008) Radiofrequency ablation of hepatocellular carcinoma: long-term outcome and prognostic factors. Eur J Radiol 67:336–347PubMedGoogle Scholar
- Ueno S, Sakoda M, Kubo F, Hiwatashi K, Tateno T, Baba Y et al (2009) Surgical resection versus radiofrequency ablation for small hepatocellular carcinomas within the Milan criteria. J Hepatobiliary Pancreat Surg 16:359–366PubMedGoogle Scholar
- Wiersinga WJ, Jansen MC, Straatsburg IH, Davids PH, Klaase JM, Gouma DJ et al (2003) Lesion progression with time and the effect of vascular occlusion following radiofrequency ablation of the liver. Br J Surg 90:306–312PubMedGoogle Scholar
- Goldberg SN, Hahn PF, Tanabe KK, Mueller PR, Schima W, Athanasoulis CA et al (1998) Percutaneous radiofrequency tissue ablation: does perfusion-mediated tissue cooling limit coagulation necrosis? J Vasc Interv Radiol 9:101–111PubMedGoogle Scholar
- Patterson EJ, Scudamore CH, Owen DA, Nagy AG, Buczkowski AK (1998) Radiofrequency ablation of porcine liver in vivo: effects of blood flow and treatment time on lesion size. Ann Surg 227:559–565PubMedPubMed CentralGoogle Scholar
- Miao Y, Ni Y, Mulier S, Wang K, Hoey MF, Mulier P et al (1997) Ex vivo experiment on radiofrequency liver ablation with saline infusion through a screw-tip cannulated electrode. J Surg Res 71:19–24PubMedGoogle Scholar
- Goldberg SN, Gazelle GS, Dawson SL, Rittman WJ, Mueller PR, Rosenthal DI (1995) Tissue ablation with radiofrequency using multiprobe arrays. Acad Radiol 2:670–674PubMedGoogle Scholar
- Veenendaal LM, Borel Rinkes IH, Van Hillegersberg R (2006) Multipolar radiofrequency ablation of large hepatic metastases of endocrine tumours. Eur J Gastroenterol Hepatol 18:89–92PubMedGoogle Scholar
- Rhim H (2005) Complications of radiofrequency ablation in hepatocellular carcinoma. Abdom Imaging 30:409–418PubMedGoogle Scholar
- Llovet JM, Vilana R, Bru C, Bianchi L, Salmeron JM, Boix L et al (2001) Increased risk of tumor seeding after percutaneous radiofrequency ablation for single hepatocellular carcinoma. Hepatology 33:1124–1129PubMedGoogle Scholar
- Jaskolka JD, Asch MR, Kachura JR, Ho CS, Ossip M, Wong F et al (2005) Needle tract seeding after radiofrequency ablation of hepatic tumors. J Vasc Interv Radiol 16:485–491PubMedGoogle Scholar
- Livraghi T, Lazzaroni S, Meloni F, Solbiati L (2005) Risk of tumour seeding after percutaneous radiofrequency ablation for hepatocellular carcinoma. Br J Surg 92:856–858PubMedGoogle Scholar
- Imamura J, Tateishi R, Shiina S, Goto E, Sato T, Ohki T et al (2008) Neoplastic seeding after radiofrequency ablation for hepatocellular carcinoma. Am J Gastroenterol 103:3057–3062PubMedGoogle Scholar
- Snoeren N, Jansen MC, Rijken AM, van Hillegersberg R, Slooter G, Klaase J et al (2009) Assessment of viable tumour tissue attached to needle applicators after local ablation of liver tumours. Dig Surg 26:56–62PubMedGoogle Scholar
- Livraghi T (2009) Single HCC smaller than 2 cm: surgery or ablation: Interventional oncologist’s perspective. J Hepatobiliary Pancreat SurgGoogle Scholar
- Takayama T, Makuuchi M, Hasegawa K (2009) Single HCC smaller than 2 cm: surgery or ablation?: Surgeon’s perspective. J Hepatobiliary Pancreat SurgGoogle Scholar
- Chen MS, Li JQ, Zheng Y, Guo RP, Liang HH, Zhang YQ et al (2006) A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg 243:321–328PubMedPubMed CentralGoogle Scholar
- Rubinsky B, Lee CY, Bastacky J, Onik G (1990) The process of freezing and the mechanism of damage during hepatic cryosurgery. Cryobiology 27:85–97PubMedGoogle Scholar
- Hinshaw JL, Lee FT Jr (2007) Cryoablation for liver cancer. Tech Vasc Interv Radiol 10:47–57PubMedGoogle Scholar
- Haddad FF, Chapman WC, Wright JK, Blair TK, Pinson CW (1998) Clinical experience with cryosurgery for advanced hepatobiliary tumors. J Surg Res 75:103–108PubMedGoogle Scholar
- Zhou XD, Tang ZY (1998) Cryotherapy for primary liver cancer. Semin Surg Oncol 14:171–174PubMedGoogle Scholar
- Pearson AS, Izzo F, Fleming RY, Ellis LM, Delrio P, Roh MS et al (1999) Intraoperative radiofrequency ablation or cryoablation for hepatic malignancies. Am J Surg 178:592–599PubMedGoogle Scholar
- Seifert JK, Morris DL (1999) World survey on the complications of hepatic and prostate cryotherapy. World J Surg 23:109–113PubMedGoogle Scholar
- Dong BW, Liang P, Yu XL, Zeng XQ, Wang PJ, Su L et al (1998) Sonographically guided microwave coagulation treatment of liver cancer: an experimental and clinical study. AJR Am J Roentgenol 171:449–454PubMedGoogle Scholar
- Lu MD, Chen JW, Xie XY, Liu L, Huang XQ, Liang LJ et al (2001) Hepatocellular carcinoma: US-guided percutaneous microwave coagulation therapy. Radiology 221:167–172PubMedGoogle Scholar
- Dong B, Liang P, Yu X, Su L, Yu D, Cheng Z et al (2003) Percutaneous sonographically guided microwave coagulation therapy for hepatocellular carcinoma: results in 234 patients. AJR Am J Roentgenol 180:1547–1555PubMedGoogle Scholar
- Liang P, Dong B, Yu X, Yu D, Wang Y, Feng L et al (2005) Prognostic factors for survival in patients with hepatocellular carcinoma after percutaneous microwave ablation. Radiology 235:299–307PubMedGoogle Scholar
- Seki T, Wakabayashi M, Nakagawa T, Imamura M, Tamai T, Nishimura A et al (1999) Percutaneous microwave coagulation therapy for patients with small hepatocellular carcinoma: comparison with percutaneous ethanol injection therapy. Cancer 85:1694–1702PubMedGoogle Scholar
- Ohmoto K, Yoshioka N, Tomiyama Y, Shibata N, Kawase T, Yoshida K et al (2006) Thermal ablation therapy for hepatocellular carcinoma: comparison between radiofrequency ablation and percutaneous microwave coagulation therapy. Hepatogastroenterology 53:651–654PubMedGoogle Scholar
- Ohmoto K, Yoshioka N, Tomiyama Y, Shibata N, Kawase T, Yoshida K et al (2007) Radiofrequency ablation versus percutaneous microwave coagulation therapy for small hepatocellular carcinomas: a retrospective comparative study. Hepatogastroenterology 54:985–989PubMedGoogle Scholar
- Ohmoto K, Yoshioka N, Tomiyama Y, Shibata N, Kawase T, Yoshida K et al (2009) Comparison of therapeutic effects between radiofrequency ablation and percutaneous microwave coagulation therapy for small hepatocellular carcinomas. J Gastroenterol Hepatol 24:223–227PubMedGoogle Scholar
- Lu MD, Xu HX, Xie XY, Yin XY, Chen JW, Kuang M et al (2005) Percutaneous microwave and radiofrequency ablation for hepatocellular carcinoma: a retrospective comparative study. J Gastroenterol 40:1054–1060PubMedGoogle Scholar
- Shibata T, Iimuro Y, Yamamoto Y, Maetani Y, Ametani F, Itoh K et al (2002) Small hepatocellular carcinoma: comparison of radio-frequency ablation and percutaneous microwave coagulation therapy. Radiology 223:331–337PubMedGoogle Scholar
- Vogl TJ, Eichler K, Straub R, Engelmann K, Zangos S, Woitaschek D et al (2001) Laser-induced thermotherapy of malignant liver tumors: general principals, equipment(s), procedure(s)-side effects, complications and results. Eur J Ultrasound 13:117–127PubMedGoogle Scholar
- Germer CT, Roggan A, Ritz JP, Isbert C, Albrecht D, Muller G et al (1998) Optical properties of native and coagulated human liver tissue and liver metastases in the near infrared range. Lasers Surg Med 23:194–203PubMedGoogle Scholar
- Gough-Palmer AL, Gedroyc WM (2008) Laser ablation of hepatocellular carcinoma—a review. World J Gastroenterol 14:7170–7174PubMedPubMed CentralGoogle Scholar
- Pacella CM, Bizzarri G, Magnolfi F, Cecconi P, Caspani B, Anelli V et al (2001) Laser thermal ablation in the treatment of small hepatocellular carcinoma: results in 74 patients. Radiology 221:712–720PubMedGoogle Scholar
- Pacella CM, Bizzarri G, Francica G, Bianchini A, De NS, Pacella S et al (2005) Percutaneous laser ablation in the treatment of hepatocellular carcinoma with small tumors: analysis of factors affecting the achievement of tumor necrosis. J Vasc Interv Radiol 16:1447–1457PubMedGoogle Scholar
- Pacella CM, Bizzarri G, Francica G, Forlini G, Petrolati A, Valle D et al (2006) Analysis of factors predicting survival in patients with hepatocellular carcinoma treated with percutaneous laser ablation. J Hepatol 44:902–909PubMedGoogle Scholar
- Pacella CM, Francica G, Di Lascio FM, Arienti V, Antico E, Caspani B et al (2009) Long-term outcome of cirrhotic patients with early hepatocellular carcinoma treated with ultrasound-guided percutaneous laser ablation: a retrospective analysis. J Clin Oncol 27:2615–2621PubMedGoogle Scholar
- Dick EA, Joarder R, de JM T-R, SD THC, Foster GR et al (2003) MR-guided laser thermal ablation of primary and secondary liver tumours. Clin Radiol 58:112–120PubMedGoogle Scholar
- Eichler K, Mack MG, Straub R, Engelmann K, Zangos S, Woitaschek D et al (2001) Oligonodular hepatocellular carcinoma (HCC): MR-controlled laser-induced thermotherapy. Radiologe 41:915–922PubMedGoogle Scholar
- Arienti V, Pretolani S, Pacella CM, Magnolfi F, Caspani B, Francica G et al (2008) Complications of laser ablation for hepatocellular carcinoma: a multicenter study. Radiology 246:947–955PubMedGoogle Scholar
- Pompili M, Pacella CM, Francica G, Angelico M, Tisone G, Craboledda P et al (2009) Percutaneous laser ablation of hepatocellular carcinoma in patients with liver cirrhosis awaiting liver transplantation. Eur J RadiolGoogle Scholar
- Ferrari FS, Megliola A, Scorzelli A, Stella A, Vigni F, Drudi FM et al (2007) Treatment of small HCC through radiofrequency ablation and laser ablation. Comparison of techniques and long-term results. Radiol Med 112:377–393PubMedGoogle Scholar
- Chen L, Rivens I, ter Haar G, Riddler S, Hill CR, Bensted JP (1993) Histological changes in rat liver tumours treated with high-intensity focused ultrasound. Ultrasound Med Biol 19:67–74PubMedGoogle Scholar
- Wu F, Wang ZB, Chen WZ, Zhu H, Bai J, Zou JZ et al (2004) Extracorporeal high intensity focused ultrasound ablation in the treatment of patients with large hepatocellular carcinoma. Ann Surg Oncol 11:1061–1069PubMedGoogle Scholar
- Zhu H, Zhou K, Zhang L, Jin C, Peng S, Yang W et al (2008) High intensity focused ultrasound (HIFU) therapy for local treatment of hepatocellular carcinoma: Role of partial rib resection. Eur J RadiolGoogle Scholar
- Civale J, Clarke R, Rivens I, ter Haar G (2006) The use of a segmented transducer for rib sparing in HIFU treatments. Ultrasound Med Biol 32:1753–1761PubMedGoogle Scholar
- Liu HL, Chang H, Chen WS, Shih TC, Hsiao JK, Lin WL (2007) Feasibility of transrib focused ultrasound thermal ablation for liver tumors using a spherically curved 2D array: a numerical study. Med Phys 34:3436–3448PubMedGoogle Scholar
- Breedis C, Young G (1954) The blood supply of neoplasms in the liver. Am J Pathol 30:969–977PubMedPubMed CentralGoogle Scholar
- Marelli L, Stigliano R, Triantos C, Senzolo M, Cholongitas E, Davies N et al (2007) Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol 30:6–25PubMedGoogle Scholar
- Pleguezuelo M, Marelli L, Misseri M, Germani G, Calvaruso V, Xiruochakis E et al (2008) TACE versus TAE as therapy for hepatocellular carcinoma. Expert Rev Anticancer Ther 8:1623–1641PubMedGoogle Scholar
- Kanematsu T, Inokuchi K, Sugimachi K, Furuta T, Sonoda T, Tamura S et al (1984) Selective effects of Lipiodolized antitumor agents. J Surg Oncol 25:218–226PubMedGoogle Scholar
- Bhattacharya S, Novell JR, Winslet MC, Hobbs KE (1994) Iodized oil in the treatment of hepatocellular carcinoma. Br J Surg 81:1563–1571PubMedGoogle Scholar
- Geschwind JF, Ramsey DE, Cleffken B, van der Wal BC, Kobeiter H, Juluru K et al (2003) Transcatheter arterial chemoembolization of liver tumors: effects of embolization protocol on injectable volume of chemotherapy and subsequent arterial patency. Cardiovasc Intervent Radiol 26:111–117PubMedGoogle Scholar
- Llovet JM, Real MI, Montana X, Planas R, Coll S, Aponte J et al (2002) Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 359:1734–1739PubMedGoogle Scholar
- Lo CM, Ngan H, Tso WK, Liu CL, Lam CM, Poon RT et al (2002) Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 35:1164–1171PubMedGoogle Scholar
- Llovet JM, Bruix J (2003) Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology 37:429–442PubMedGoogle Scholar
- Lin DY, Liaw YF, Lee TY, Lai CM (1988) Hepatic arterial embolization in patients with unresectable hepatocellular carcinoma—a randomized controlled trial. Gastroenterology 94:453–456PubMedGoogle Scholar
- Pelletier G, Roche A, Ink O, Anciaux ML, Derhy S, Rougier P et al (1990) A randomized trial of hepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma. J Hepatol 11:181–184PubMedGoogle Scholar
- Groupe d’Etude et de Traitement du Carcinome Hepatocellulaire (1995) A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. N Engl J Med 332:1256–1261Google Scholar
- Pelletier G, Ducreux M, Gay F, Luboinski M, Hagege H, Dao T et al (1998) Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: a multicenter randomized trial. Groupe CHC J Hepatol 29:129–134PubMedGoogle Scholar
- Wigmore SJ, Redhead DN, Thomson BN, Currie EJ, Parks RW, Madhavan KK et al (2003) Postchemoembolisation syndrome-tumour necrosis or hepatocyte injury? Br J Cancer 89:1423–1427PubMedPubMed CentralGoogle Scholar
- Bruix J, Sala M, Llovet JM (2004) Chemoembolization for hepatocellular carcinoma. Gastroenterology 127:S179–S188PubMedGoogle Scholar
- Buijs M, Vossen JA, Frangakis C, Hong K, Georgiades CS, Chen Y et al (2008) Nonresectable hepatocellular carcinoma: long-term toxicity in patients treated with transarterial chemoembolization-single-center experience. Radiology 249:346–354PubMedGoogle Scholar
- Huo TI, Wu JC, Lee PC, Chang FY, Lee SD (2004) Incidence and risk factors for acute renal failure in patients with hepatocellular carcinoma undergoing transarterial chemoembolization: a prospective study. Liver Int 24:210–215PubMedGoogle Scholar
- Mathupala SP, Rempel A, Pedersen PL (2001) Glucose catabolism in cancer cells: identification and characterization of a marked activation response of the type II hexokinase gene to hypoxic conditions. J Biol Chem 276:43407–43412PubMedGoogle Scholar
- Lau WY, Lai EC (2008) Hepatocellular carcinoma: current management and recent advances. Hepatobiliary Pancreat Dis Int 7:237–257PubMedGoogle Scholar
- Hong K, Khwaja A, Liapi E, Torbenson MS, Georgiades CS, Geschwind JF (2006) New intra-arterial drug delivery system for the treatment of liver cancer: preclinical assessment in a rabbit model of liver cancer. Clin Cancer Res 12:2563–2567PubMedGoogle Scholar
- Varela M, Real MI, Burrel M, Forner A, Sala M, Brunet M et al (2007) Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol 46:474–481PubMedGoogle Scholar
- Lewis AL, Gonzalez MV, Lloyd AW, Hall B, Tang Y, Willis SL et al (2006) DC bead: in vitro characterization of a drug-delivery device for transarterial chemoembolization. J Vasc Interv Radiol 17:335–342PubMedGoogle Scholar
- Poon RT, Tso WK, Pang RW, Ng KK, Woo R, Tai KS et al (2007) A phase I/II trial of chemoembolization for hepatocellular carcinoma using a novel intra-arterial drug-eluting bead. Clin Gastroenterol Hepatol 5:1100–1108PubMedGoogle Scholar
- Malagari K, Chatzimichael K, Alexopoulou E, Kelekis A, Hall B, Dourakis S et al (2008) Transarterial chemoembolization of unresectable hepatocellular carcinoma with drug eluting beads: results of an open-label study of 62 patients. Cardiovasc Intervent Radiol 31:269–280PubMedGoogle Scholar
- Malagari K, Alexopoulou E, Chatzimichail K, Hall B, Koskinas J, Ryan S et al (2008) Transcatheter chemoembolization in the treatment of HCC in patients not eligible for curative treatments: midterm results of doxorubicin-loaded DC bead. Abdom Imaging 33:512–519PubMedGoogle Scholar
- Grosso M, Vignali C, Quaretti P, Nicolini A, Melchiorre F, Gallarato G et al (2008) Transarterial chemoembolization for hepatocellular carcinoma with drug-eluting microspheres: preliminary results from an Italian multicentre study. Cardiovasc Intervent Radiol 31:1141–1149PubMedGoogle Scholar
- JA Ingold, GB Reed, HS Kaplan, MA Bagshaw (1965) Radiation hepatitis. Am J Roentgenol Radium Ther Nucl Med 93:200–208Google Scholar
- Lawrence TS, Robertson JM, Anscher MS, Jirtle RL, Ensminger WD, Fajardo LF (1995) Hepatic toxicity resulting from cancer treatment. Int J Radiat Oncol Biol Phys 31:1237–1248PubMedGoogle Scholar
- Cheng JC, Wu JK, Huang CM, Huang DY, Cheng SH, Lin YM et al (2002) Radiation-induced liver disease after radiotherapy for hepatocellular carcinoma: clinical manifestation and dosimetric description. Radiother Oncol 63:41–45PubMedGoogle Scholar
- Kennedy AS, Nutting C, Coldwell D, Gaiser J, Drachenberg C (2004) Pathologic response and microdosimetry of (90)Y microspheres in man: review of four explanted whole livers. Int J Radiat Oncol Biol Phys 60:1552–1563PubMedGoogle Scholar
- Ariel IM (1965) Treatment of inoperable primary pancreatic and liver cancer by the intra-arterial administration of radioactive isotopes (Y90 radiating microspheres). Ann Surg 162:267–278PubMedPubMed CentralGoogle Scholar
- Sato K, Lewandowski RJ, Bui JT, Omary R, Hunter RD, Kulik L et al (2006) Treatment of unresectable primary and metastatic liver cancer with yttrium-90 microspheres (TheraSphere): assessment of hepatic arterial embolization. Cardiovasc Intervent Radiol 29:522–529PubMedGoogle Scholar
- Lau WY, Ho S, Leung TW, Chan M, Ho R, Johnson PJ et al (1998) Selective internal radiation therapy for nonresectable hepatocellular carcinoma with intraarterial infusion of 90yttrium microspheres. Int J Radiat Oncol Biol Phys 40:583–592PubMedGoogle Scholar
- Dancey JE, Shepherd FA, Paul K, Sniderman KW, Houle S, Gabrys J et al (2000) Treatment of nonresectable hepatocellular carcinoma with intrahepatic 90Y-microspheres. J Nucl Med 41:1673–1681PubMedGoogle Scholar
- Carr BI (2004) Hepatic arterial 90Yttrium glass microspheres (Therasphere) for unresectable hepatocellular carcinoma: interim safety and survival data on 65 patients. Liver Transpl 10:S107–S110PubMedGoogle Scholar
- Geschwind JF, Salem R, Carr BI, Soulen MC, Thurston KG, Goin KA et al (2004) Yttrium-90 microspheres for the treatment of hepatocellular carcinoma. Gastroenterology 127:S194–S205PubMedGoogle Scholar
- Goin JE, Salem R, Carr BI, Dancey JE, Soulen MC, Geschwind JF et al (2005) Treatment of unresectable hepatocellular carcinoma with intrahepatic yttrium 90 microspheres: a risk-stratification analysis. J Vasc Interv Radiol 16:195–203PubMedGoogle Scholar
- Salem R, Lewandowski RJ, Atassi B, Gordon SC, Gates VL, Barakat O et al (2005) Treatment of unresectable hepatocellular carcinoma with use of 90Y microspheres (TheraSphere): safety, tumor response, and survival. J Vasc Interv Radiol 16:1627–1639PubMedGoogle Scholar
- Sangro B, Bilbao JI, Boan J, Martinez-Cuesta A, Benito A, Rodriguez J et al (2006) Radioembolization using 90Y-resin microspheres for patients with advanced hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 66:792–800PubMedGoogle Scholar
- Young JY, Rhee TK, Atassi B, Gates VL, Kulik L, Mulcahy MF et al (2007) Radiation dose limits and liver toxicities resulting from multiple yttrium-90 radioembolization treatments for hepatocellular carcinoma. J Vasc Interv Radiol 18:1375–1382PubMedGoogle Scholar
- Kulik LM, Carr BI, Mulcahy MF, Lewandowski RJ, Atassi B, Ryu RK et al (2008) Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis. Hepatology 47:71–81PubMedGoogle Scholar
- Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK et al (2001) Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 35:421–430PubMedGoogle Scholar
- Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205–216PubMedGoogle Scholar
- Ibrahim SM, Lewandowski RJ, Sato KT, Gates VL, Kulik L, Mulcahy MF et al (2008) Radioembolization for the treatment of unresectable hepatocellular carcinoma: a clinical review. World J Gastroenterol 14:1664–1669PubMedPubMed CentralGoogle Scholar
- Murthy R, Nunez R, Szklaruk J, Erwin W, Madoff DC, Gupta S et al (2005) Yttrium-90 microsphere therapy for hepatic malignancy: devices, indications, technical considerations, and potential complications. Radiographics 25(Suppl 1):S41–S55PubMedGoogle Scholar
- Murthy R, Brown DB, Salem R, Meranze SG, Coldwell DM, Krishnan S et al (2007) Gastrointestinal complications associated with hepatic arterial Yttrium-90 microsphere therapy. J Vasc Interv Radiol 18:553–561PubMedGoogle Scholar
- Carretero C, Munoz-Navas M, Betes M, Angos R, Subtil JC, Fernandez-Urien I et al (2007) Gastroduodenal injury after radioembolization of hepatic tumors. Am J Gastroenterol 102:1216–1220PubMedGoogle Scholar
- Leung TW, Lau WY, Ho SK, Ward SC, Chow JH, Chan MS et al (1995) Radiation pneumonitis after selective internal radiation treatment with intraarterial 90yttrium-microspheres for inoperable hepatic tumors. Int J Radiat Oncol Biol Phys 33:919–924PubMedGoogle Scholar
- Lau WY, Ho SK, Yu SC, Lai EC, Liew CT, Leung TW (2004) Salvage surgery following downstaging of unresectable hepatocellular carcinoma. Ann Surg 240:299–305PubMedPubMed CentralGoogle Scholar
- Kulik LM, Mulcahy MF, Hunter RD, Nemcek AA Jr, Abecassis MM, Salem R (2005) Use of yttrium-90 microspheres (TheraSphere) in a patient with unresectable hepatocellular carcinoma leading to liver transplantation: a case report. Liver Transpl 11:1127–1131PubMedGoogle Scholar
- Kulik LM, Atassi B, van Holsbeck L, Souman T, Lewandowski RJ, Mulcahy MF et al (2006) Yttrium-90 microspheres (TheraSphere) treatment of unresectable hepatocellular carcinoma: downstaging to resection, RFA and bridge to transplantation. J Surg Oncol 94:572–586PubMedGoogle Scholar
- Zhang YJ, Liang HH, Chen MS, Guo RP, Li JQ, Zheng Y et al (2007) Hepatocellular carcinoma treated with radiofrequency ablation with or without ethanol injection: a prospective randomized trial. Radiology 244:599–607PubMedGoogle Scholar
- Bartolozzi C, Lencioni R, Caramella D, Vignali C, Cioni R, Mazzeo S et al (1995) Treatment of large HCC: transcatheter arterial chemoembolization combined with percutaneous ethanol injection versus repeated transcatheter arterial chemoembolization. Radiology 197:812–818PubMedGoogle Scholar
- Koda M, Murawaki Y, Mitsuda A, Oyama K, Okamoto K, Idobe Y et al (2001) Combination therapy with transcatheter arterial chemoembolization and percutaneous ethanol injection compared with percutaneous ethanol injection alone for patients with small hepatocellular carcinoma: a randomized control study. Cancer 92:1516–1524PubMedGoogle Scholar
- Akamatsu M, Yoshida H, Obi S, Sato S, Koike Y, Fujishima T et al (2004) Evaluation of transcatheter arterial embolization prior to percutaneous tumor ablation in patients with hepatocellular carcinoma: a randomized controlled trial. Liver Int 24:625–629PubMedGoogle Scholar
- Becker G, Soezgen T, Olschewski M, Laubenberger J, Blum HE, Allgaier HP (2005) Combined TACE and PEI for palliative treatment of unresectable hepatocellular carcinoma. World J Gastroenterol 11:6104–6109PubMedPubMed CentralGoogle Scholar
- Marelli L, Stigliano R, Triantos C, Senzolo M, Cholongitas E, Davies N et al (2006) Treatment outcomes for hepatocellular carcinoma using chemoembolization in combination with other therapies. Cancer Treat Rev 32:594–606PubMedGoogle Scholar
This article is published under license to BioMed Central Ltd.Open Access This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.